Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Regenxbio Inc (RGNX)

REGENXBIO To Report Duchenne Muscular Dystrophy Trial Results In Early Q2 2026 3/9/2026 11:06:44 AM

REGENXBIO Q4 Net Loss/shr $1.30 Vs. Loss/shr $1.01 Last Year 3/5/2026 7:12:01 AM

Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace 2/13/2026 10:39:05 AM

Regenxbio Receives FDA Complete Response Letter For RGX-121 BLA In MPS II 2/10/2026 7:08:18 AM

Morning Market Movers: ABP, TECX, UPWK, ICHR See Big Swings 2/10/2026 6:43:23 AM

REGENXBIO Plunges After FDA Declines Approval Of RGX-121 For Treatment Of Mucopolysaccharidosis II 2/10/2026 4:48:16 AM

Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE 1/30/2026 12:37:49 PM

REGENXBIO Shares Decline 17% After FDA Imposed Clinical Holds On Gene Therapy Programs 1/28/2026 1:01:38 PM

REGENXBIO Plunges After FDA Places Clinical Hold On RGX-111 And RGX-121 Trials For MPS I And II 1/28/2026 10:19:26 AM

Why Is REGENXBIO Stock Falling In Pre-market? 1/28/2026 7:53:09 AM

FDA Places Clinical Hold On REGENXBIO’s RGX-111 And RGX-121 Gene Therapy Trials 1/28/2026 7:32:19 AM

Biotech Stocks Facing FDA Decision In February 2026 1/27/2026 10:44:22 PM

Older Articles

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap